Eligibility Criteria

• Inclusion Criteria: 1. Male or female participants ? 18 years of age at the time of signing the informed consent 2. Have an ECOG performance status score of 0 to 2 3. Have an established cytopathologically confirmed diagnosis of BCR::ABL1 positive CML in CP, and meet at least one of the following: ? Participants without the BCR::ABL1 T315Im, who meet one of the following and have experienced treatment failure, suboptimal response, or treatment intolerance as determined by the investigator. o Received 2 or more active site targeting TKIs OR o Received frontline therapy with dasatinib, nilotinib, or bosutinib and are ineligible for alternative TKIs per the investigator?s discretion In Part 1 only, participants with BCR::ABL1 T315Im who received 1 or more active site targeting TKIs Participants who are intolerant of asciminib Exclusion criteria: 1. Has known ABL1 myristoyl domain resistance mutations 2. Has CML in accelerated or blast phase 3. For Part 2 only, CML with T315I mutation

Contact Information

    Kelly Jenkins, MSN, CNL, RN

    (706) 721-2505

   kejenkins@augusta.edu